Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Sanofi Securities Litigation v. Meeker

United States District Court, S.D. New York

January 28, 2015

IN RE SANOFI SECURITIES LITIGATION; AG FUNDS, L.P., et al., Plaintiffs,
v.
SANOFI, GENZYME, CHRISTOPHER VIEHBACHER, DAVID MEEKER, and JEROME CONTAMINE, Defendants,

Page 511

[Copyrighted Material Omitted]

Page 512

[Copyrighted Material Omitted]

Page 513

[Copyrighted Material Omitted]

Page 514

[Copyrighted Material Omitted]

Page 515

John Solak, individually and on behalf of all others similarly situated, Plaintiff (1:13-cv-08806-PAE), Pro se.

For Jeffrey Maas, Assaf David Margalit, Movants (1:13-cv-08806-PAE): Jeremy Alan Lieberman, Pomerantz LLP, New York, NY.

For Gen. Partner Glenn Tongue, Deerhaven Capital Mgmt., Movants (1:13-cv-08806-PAE): Brett D Stecker, Daniella Quitt, Robert I. Harwood, Harwood Feffer LLP, New York, NY; Christopher L. Nelson, The Weiser Law Firm, P.C. Berwyn, PA.

For Sanofi, Christopher Viehbacher, David Meeker, Jerome Contamine, Genzyme Corporation, Defendants (1:13-cv-08806-PAE, 1:14-cv-02211-PAE): John A. Neuwirth, LEAD ATTORNEY, Weil, Gotshal & Manges LLP (NYC), New York, NY; Joshua Sanders Amsel, LEAD ATTORNEY, Weil, Gotshal & Manges LLP, New York, NY.

For AG Funds, L.P., AG MM, L.P., AG Super Fund International, L.P., AG Princess, L.P., Nutmeg Partners, L.P., AG Super Fund, L.P., Aristeia Horizons, L.P., Windermere Ireland Fund plc, Compass ESMA, L.P., Compass TSMA, L.P., Xeropolis L.L.C., Oz Master Fund, Ltd., Oz Eureka Fund, L.P., Gordel Capital Limited, OZ Europe Master Fund, Ltd., OZ Global Special Investments Master Fund, L.P., OZ Select Master Fund, Ltd., OZ Global Equity Opportunities Master Fund, Ltd., OZ Enhanced Master Fund, Ltd., Sapelo L.L.C., Whitebox Concentrated Convertible Arbitrage Partners, L.P., Whitebox Credit Arbitrage Partners, L.P., Whitebox Asymmetric Partners, L.P., Whitebox Multistrategy Partners, L.P., Pandora Select Partners, L.P., Whitebox Institutional Partners, L.P., Whitebox Special Opportunities Fund Series B Partners, L.P., Whitebox Special Opportunities Fund LP - Series O, Plaintiffs (1:14-cv-02211-PAE): John B. Orenstein, LEAD ATTORNEY, Jeff I Ross, PRO HAC VICE, Ross & Orenstein LLC, Minneapolis, MN.

Page 516

OPINION & ORDER

Paul A. Engelmayer, United States District Judge.

In these related cases brought under the securities laws, plaintiffs claim that the

Page 517

pharmaceutical company Sanofi, its predecessor Genzyme, and three company executives (collectively, " defendants," " Sanofi," or " the company" ) made false and misleading statements about Lemtrada, a multiple sclerosis (" MS" ) drug, while it was under review by the U.S. Food and Drug Administration (" FDA" ). Although plaintiffs find multiple faults with Sanofi's public pronouncements, their core allegation is that defendants failed to disclose concerns the FDA had expressed about the " single-blind" design used in Lemtrada's clinical trials, and that this omission made Sanofi's public statements about Lemtrada false and misleading.

Plaintiffs allege violations of § § 10(b), 18, and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. § § 78a et seq. (the " Exchange Act" ); § § 11 and 12 of the Securities Act of 1933, 15 U.S.C. § 77a et seq. (the " Securities Act" ); and state blue sky laws. Pending now are defendants' motions to dismiss both complaints for failure to state a claim, under Federal Rules of Civil Procedure 12(b)(6) and 9(b). ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.